Sijunzi decoction granules in the prevention and treatment of recurrence of colorectal adenoma: Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial

被引:4
|
作者
Ni, Wenjing [1 ,2 ]
Liu, Tao [1 ]
Liu, Yujing [1 ,2 ]
Lu, Lu [1 ,2 ]
Zhou, Bingduo [3 ]
Dai, Yancheng [4 ]
Zhao, Hang [5 ]
Xu, Hanchen [1 ,2 ]
Ji, Guang [1 ,2 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Inst Digest Dis, Shanghai, Peoples R China
[2] Shanghai Frontier Res Ctr Dis & Syndrome Biol Infl, Shanghai, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Tradit Chinese & Western M, Dept Gastroenterol, Shanghai, Peoples R China
[4] Shanghai Univ Tradit Chinese Med, Shanghai Tradit Chinese Med Integrated Hosp, Dept Gastroenterol, Shanghai, Peoples R China
[5] Shanghai Univ Tradit Chinese Med, Shanghai Municipal Hosp Tradit Chinese Med, Dept Gastroenterol, Shanghai, Peoples R China
关键词
traditional Chinese medicine; Sijunzi decoction; randomized controlled trial; colorectal adenoma; spleen deficiency syndrome; ENDOSCOPIC MUCOSAL RESECTION; VITAMIN-D; CANCER; CALCIUM;
D O I
10.3389/fphar.2023.1175811
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The recurrence of colorectal adenomas (CRAs) after endoscopy predisposes patients to a risk of colorectal cancer. Guided by the traditional Chinese medicine (TCM), patients with colorectal diseases usually manifest with spleen deficiency syndrome (SDS) and are treated with Sijunzi decoction (SJZD). Therefore, this trial aims to explore the efficacy and safety of SJZD in the prevention and treatment of CRAs recurrence.Methods: SJZD on prevention and treatment of CRAs recurrence after resection: a multicenter, randomized, double-blind, placebo-controlled trial was designed. Patients who undergo polypectomy of CRAs will be recruited and randomized into a SJZD group and a placebo group in a 1:1 ratio. The intervention phase will be 12 months. The follow-up period will last 24 months. The primary outcome is the CRA recurrence rate after intervention. The secondary outcomes include the CRA recurrence rate at the second year post-polypectomy, the pathological type of adenoma and the alterations in SDS scores after intervention.Discussion: Previous clinical practice has observed the sound effect of SJZD in the context of gastrointestinal diseases. A number of experiments have also validated the active components in SJZD. This trial aims to provide tangible evidence for the usage of SJZD, hoping to reduce the recurrence of CRAs.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Sijunzi decoction granules for the treatment of advanced refractory colorectal cancer: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial
    Nie, Shuchang
    Su, Yingyu
    Lu, Lu
    Jing, Yanhua
    Jiang, Zenghua
    Xu, Yangxian
    Wu, Tingting
    Zhong, Yi
    Wu, Hao
    Chen, Junming
    Ruan, Ming
    Zheng, Lan
    Wang, Liyu
    Gong, Yabin
    Ji, Guang
    Xu, Hanchen
    FRONTIERS IN MEDICINE, 2025, 12
  • [2] Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial of Mesalamine for the Prevention of Recurrence of Diverticulitis
    Kruis, Wolfgang
    Eisenbach, Thomas
    Loehr, Hanns
    Mueser, Moritz
    Tan, Gie T.
    Lukas, Milan
    Vich, Tomas
    Bunganic, Ivan
    Pokrotnieks, Juris
    Derova, Jelena
    Kondrackiene, Jurate
    Safadi, Rifaat
    Tuculanu, Daniel
    Tulassay, Zsolt
    Banai, Janos
    Dilger, Karin
    Greinwald, Roland
    Mohrbacher, Ralf
    Spiller, Robin C.
    GASTROENTEROLOGY, 2013, 144 (05) : S139 - S139
  • [3] Efficacy and safety of Sijunzi Decoction for chronic fatigue syndrome with spleen deficiency pattern: study protocol for a randomized, double-blind, placebo-controlled trial
    Dai, Liang
    Zhou, Wen-Jun
    Wang, Miao
    Zhou, Shi-Gao
    Ji, Guang
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (20)
  • [4] Tiaochang Xiaoliu Decoction Granules prevent the recurrence of colorectal adenoma: a study protocol for a randomized controlled trial
    Zhong, Cailing
    Wu, Shaohua
    Chen, Chunhui
    Huang, Haocheng
    Mo, Jiahao
    Yang, Xiaobo
    Chen, Yan
    Zhang, Beiping
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (04) : 4897 - 4905
  • [5] Gabapentin in the treatment of fibromyalgia - A randomized, double-blind, placebo-controlled, multicenter trial
    Arnold, Lesley M.
    Goldenberg, Don L.
    Stanford, Sharon B.
    Lalonde, Justine K.
    Sandhu, H. S.
    Keck, Paul E., Jr.
    Welge, Jeffrey A.
    Bishop, Fred
    Stanford, Kevin E.
    Hess, Evelyn V.
    Hudson, James I.
    ARTHRITIS AND RHEUMATISM, 2007, 56 (04): : 1336 - 1344
  • [6] Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma
    Schoen, Robert E.
    Boardman, Lisa A.
    Cruz-Correa, Marcia
    Bansal, Ajay
    Kastenberg, David
    Hur, Chin
    Dzubinski, Lynda
    Kaufman, Sharon F.
    Rodriguez, Luz M.
    Richmond, Ellen
    Umar, Asad
    Szabo, Eva
    Salazar, Andres
    McKolanis, John
    Beatty, Pamela
    Pai, Reetesh K.
    Singhi, Aatur D.
    Jacqueline, Camille M.
    Bao, Riyue
    Diergaarde, Brenda
    Mcmurray, Ryan P.
    Strand, Carrie
    Foster, Nathan R.
    Zahrieh, David M.
    Limburg, Paul J.
    Finn, Olivera J.
    CLINICAL CANCER RESEARCH, 2023, 29 (09) : 1678 - 1688
  • [7] MTHFR genotype and colorectal adenoma recurrence: Data from a double-blind placebo-controlled clinical trial
    Levine, A. Joan
    Wallace, Kristin
    Tsang, Shirley
    Haile, Robert W.
    Saibil, Fred
    Ahnen, Dennis
    Cole, Bernard F.
    Barry, Elizabeth L.
    Munroe, David J.
    Ali, Iqbal U.
    Ueland, Per
    Baron, John A.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (09) : 2409 - 2415
  • [8] SULFASALAZINE IN THE TREATMENT OF SPONDYLARTHROPATHY - A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    DOUGADOS, M
    VANDERLINDEN, S
    LEIRISALOREPO, M
    HUITFELDT, B
    JUHLIN, R
    VEYS, E
    ZEIDLER, H
    KVIEN, TK
    OLIVIERI, I
    DIJKMANS, B
    BERTOUCH, J
    BROOKS, P
    EDMONDS, J
    MAJOR, G
    AMOR, B
    CALIN, A
    ARTHRITIS AND RHEUMATISM, 1995, 38 (05): : 618 - 627
  • [9] Pentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial
    Levin, B
    Thompson, JLP
    Levy, G
    Mitsumoto, H
    Kaufmann, P
    NEUROLOGY, 2006, 66 (11) : 1786 - 1786
  • [10] Pentoxifylline in ALS - A double-blind, randomized, multicenter, placebo-controlled trial
    Meininger, V
    Asselain, B
    Guillet, P
    Leigh, PN
    Ludolph, A
    Lacomblez, L
    Robberecht, W
    NEUROLOGY, 2006, 66 (01) : 88 - 92